Skip to main content
SpringerLink
Log in

Vinorelbine in Advanced Non–Small Cell Lung Cancer

A Pharmacoeconomic Review

  • Adis Pharmacoeconomic Drug Evaluation
  • Vinorelbine: A Pharmacoeconomic Review
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Vinorelbine is a semisynthetic vinca alkaloid that is effective against advanced non–small cell lung cancer (NSCLC). Myelosuppression is the primary dose-limiting toxicity; vinorelbine is otherwise relatively well tolerated.

Two studies assessed the cost effectiveness of vinorelbine with or without cisplatin based primarily on data from a phase III comparison with vindesine plus cisplatin. Survival and cost data from this study were supplemented with those from other sources. One model simulated total management costs for the 4986 patients diagnosed with stage IV NSCLC in Canada in 1992. The other applied US cost data to the outcomes from the phase III trial.

Using vinorelbine monotherapy or vinorelbine plus cisplatin produced a survival benefit and net cost savings compared with best supportive care according to the Canadian model (and preliminary data from a third analysis, conducted in the US).

In the Canadian analysis, incremental cost effectiveness for inpatient or outpatient vinorelbine plus cisplatin ranged from 7450 Canadian dollars ($Can) to $Can30770 (1993 values) per year of life saved (YLS) compared with outpatient cisplatin plus either etoposide or vinblastine. Cost-effectiveness ratios for vinorelbine plus cisplatin in the US analysis (1994 values) were $US18 000 (vs cisplatin plus etoposide) and $US15 500 (vs cisplatin plus vindesine) per YLS [all inpatient administration]. Detailed pharmacoeconomic comparisons with other current standard regimens (e.g. paclitaxel plus either cisplatin or carboplatin) are not available.

Sensitivity analyses suggest that the cost effectiveness of vinorelbine-based therapy is robust to changes in assumptions regarding efficacy and the cost of managing toxicity.

Limitations of the available pharmacoeconomic data include the retrospective nature of the analyses, inclusion of data from sources other than the main phase III trial (e.g. those for best supportive care and some chemotherapy regimens), and exclusion of some costs for hospitalisation and/or management of toxicity.

Conclusions. Although some limitations apply, the available data suggest that vinorelbine alone or in combination with cisplatin is cost saving compared with best supportive care for NSCLC, and that vinorelbine plus cisplatin is cost effective compared with some other combination regimens. The pharmacoeconomic placing of vinorelbine in relation to a number of other currently recommended first-line treatments for NSCLC has yet to be resolved, and data from ongoing multicentre phase III trials are awaited with interest. In the meantime, vinorelbine- based chemotherapy appears to be a suitable choice for first-line treatment of advanced NSCLC from both clinical and pharmacoeconomic perspectives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vainio H, Heseltine E. Tobacco and cancer. Cancer Res 1986 Jan; 46: 444–7

    Google Scholar 

  2. Loeb LA, Ernster VL, Warner KE, et al. Smoking and lung cancer: an overview. Cancer Res 1984 Dec; 44: 5940–5958

    PubMed  CAS  Google Scholar 

  3. Fraumeni Jr JF, Blot WJ. Lung and pleura. In: Schottenfeld D, Fraumeni Jr JF, editors. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982: 564–82

    Google Scholar 

  4. National Cancer Institute. Non-small cell lung cancer for physicians. In: PDQ information for health care professionals [online]. National Cancer Institute; 1999. Available from: http://cancernet.nci.nih.gov/clinpdq/soa/Non-smallcelllungcancerPhysician.html [Accessed 1999 Jan 1]

    Google Scholar 

  5. Kelly P, Clancy L. Is the use of chemotherapy justified in non-small cell lung cancer? Drugs Aging 1994 Jan; 4: 1–8

    Article  PubMed  CAS  Google Scholar 

  6. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non–small-cell lung cancer. J Clin Oncol 1997 Aug; 15: 2996–3018

    Google Scholar 

  7. American Cancer Society. Lung cancer 1998 facts & figures [online]. American Cancer Society; 1999. Available from: http://www.cancer.org/statistics/cff98/selectedcancers.html [Accessed 1999 Feb 22]

    Google Scholar 

  8. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 65: 5–27

    Article  Google Scholar 

  9. Travis WD, Lubin J, Ries, et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996 Jun 15; 77: 2464–70

    Article  PubMed  CAS  Google Scholar 

  10. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998 Dec; 16 (12): 3900–12

    PubMed  CAS  Google Scholar 

  11. Shoheiber O, Schrogie JJ, Johnson N. Non-small cell lung cancer: a cost of illness study [abstract]. Pharmacotherapy 1996 Jan-Feb; 16: 136

    Google Scholar 

  12. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998 Jan 1; 82: 116–26

    Article  PubMed  CAS  Google Scholar 

  13. Goa KL, Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy [published erratum appears in Drugs Aging 1995 Aug; 7(2): 116]. Drugs Aging 1994 Sep; 5: 200–34

    Article  PubMed  CAS  Google Scholar 

  14. O’Rourke MA. Historical review of trials with vinorelbine in non-small-cell lung cancer [review]. Oncology 1998; 11 Suppl. 12: 20–7

    Google Scholar 

  15. Lorusso V, Pezzella G, Catino AM, et al. Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone. Int J Oncol 1994; 6: 65–8

    Google Scholar 

  16. Le Chevalier T, Brisgand D, Douillard J-Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994 Feb; 12: 360–7

    PubMed  Google Scholar 

  17. Le Chevalier T, Pujol JL, Douillard J-Y, et al. Six year follow up of the European muticentre randomised study comparing navelbine (NVB) alone vs NVB + cisplatin (CDDP) vs vindesine (VDS) + CDDP in 612 patients (pts) with advanced non–small cell lung cancer (NSCLC). Thorax 1997; 52 Suppl. 6: 27

    Google Scholar 

  18. Gil Deza A, Balbiani L, Coppola F, et al. Phase III study of navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) stage IIIB or IV [abstract no. 1193]. Proc Am Soc Clin Oncol 1996; 15: 394

    Google Scholar 

  19. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994 Jan; 5: 37–42

    PubMed  CAS  Google Scholar 

  20. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non–small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998 Jul; 16 (7): 2459–65

    PubMed  CAS  Google Scholar 

  21. Martoni A, Guaraldi M, Piana E, et al. Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer 1998; 22: 31–8

    Article  PubMed  CAS  Google Scholar 

  22. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999 Jan; 91 (1): 66–72

    Article  Google Scholar 

  23. Crawford J, O’Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non–small-cell lung cancer. J Clin Oncol 1996 Oct; 14: 2774–84

    PubMed  CAS  Google Scholar 

  24. Hohneker JA. Safety data from North American trials of vinorelbine. Oncology Huntingt 1997 Oct; 11 Suppl. 12: 16–9

    Google Scholar 

  25. Evans WK. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC. Oncology 1998 Mar; 12 (3) Suppl. 4: 18–26

    PubMed  Google Scholar 

  26. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non–small-cell lung cancer. J Clin Oncol 1995 Sep; 13: 2166–73

    PubMed  CAS  Google Scholar 

  27. Evans WK, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer A 1996 Dec; 32A: 2249–55

    Article  PubMed  CAS  Google Scholar 

  28. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the cost of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8: 1301–9

    PubMed  CAS  Google Scholar 

  29. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992; 146: 473–81

    CAS  Google Scholar 

  30. Earle C, Evans WK, Berthelot J-M, et al. Comparison of the costs, toxicities and inconvenience of the different chemotherapy regimens for advanced non-small-cell lung cancer [abstract no. 90]. Lung Cancer 1997; 18 Suppl. 1: 26

    Article  Google Scholar 

  31. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non–small-cell lung cancer. J Clin Oncol 1985 Feb; 3 (2): 176–83

    PubMed  CAS  Google Scholar 

  32. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993 Sep 15; 85 (18): 1460–74

    Article  PubMed  CAS  Google Scholar 

  33. Gralla RJ, Grusenmeyer PA. Comparing the costs and cost-effectiveness of new chemotherapy regimens for treating non-small cell lung cancer (NSCLC) [abstract no. PP26]. Eur J Cancer A 1997 Nov; 33 Suppl. 9: S24

    Article  Google Scholar 

  34. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909

    Article  Google Scholar 

  35. Palmer AJ, Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective [see comments]. Monaldi Arch Chest Dis 1996 Aug; 51: 279–88

    PubMed  CAS  Google Scholar 

  36. Vergnenègre A, Perol M, Pham E, et al. Cost analysis of hospital treatment–two chemotherapic regimens for non-surgical non-small cell lung cancer. Lung Cancer 1996 Feb; 14: 31–44

    Article  PubMed  Google Scholar 

  37. Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non–small-cell lung cancer. Curr Probl Cancer 1998 Mar-Apr; 22: 87–132

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Allan J. Coukell, Stuart Noble & Diana Faulds

Authors
  1. Allan J. Coukell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart Noble.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coukell, A.J., Noble, S. & Faulds, D. Vinorelbine in Advanced Non–Small Cell Lung Cancer. Pharmacoeconomics 15, 405–417 (1999). https://doi.org/10.2165/00019053-199915040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199915040-00008

Keywords

Search

Navigation